Exosome assay for depression and psychosis and methods and agents for treating depression, psychosis and schizophrenia
OwnerEdward J Goetzlinventor
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to exosomal complement mediators, cytokines, and mitochondrial electron transport biomarkers and diagnostic and prognostic methods for depression, psychosis and schizophrenia. The disclosure also provides compositions for detecting exosomal complement mediators, cytokines, and mitochondrial electron transport biomarkers in biological samples as well as compositions and methods useful for treating depression, psychosis and schizophrenia.
Claims16
A method of measuring biomarkers in exosomes in a biological sample comprising:
- a) providing a biological sample comprising exosomes from a subject;
- b) enriching the sample for exosomes;
- and c) detecting the presence of the biomarkers in the exosomes, wherein the biomarkers comprise glial fibrillary acidic protein, subunit 6 of NADH-ubiquinone oxidoreductase (complex I), subunit 1 of cytochrome C oxidase (complex IV), subunit 1 of NADH-ubiquinone oxidoreductase (complex I), subunit 10 of cytochrome b-cl oxidase (complex III), humanin, and mitochondrial open-reading frame of the 12S rRNA-c (MOTS-c).
A method of measuring biomarkers in exosomes in a biological sample comprising:
- a) providing a biological sample comprising exosomes from a subject having depression or psychosis;
- b) isolating exosomes from the biological sample;
- and c) detecting the presence of biomarkers in the exosomes, wherein the biomarkers comprise glial fibrillary acidic protein, subunit 6 of NADH-ubiquinone oxidoreductase (complex I), subunit 1 of cytochrome C oxidase (complex IV), subunit 1 of NADH-ubiquinone oxidoreductase (complex I), subunit 10 of cytochrome b-cl oxidase (complex III), humanin, and mitochondrial open-reading frame of the 12S rRNA-c (MOTS-c).
A method for treating a subject, comprising the steps of:
- providing a biological sample from a subject having or suspected of having depression or psychosis, wherein the sample comprises exosomes;
- measuring the level of the biomarkers in the exosomes, wherein the biomarkers comprise glial fibrillary acidic protein, subunit 6 of NADH-ubiquinone oxidoreductase (complex I), subunit 1 of cytochrome C oxidase (complex IV), subunit 1 of NADH-ubiquinone oxidoreductase (complex I), subunit 10 of cytochrome b-cl oxidase (complex III), humanin, and mitochondrial open-reading frame of the 12S rRNA-c (MOTS-c), wherein an altered level of the biomarkers in the sample relative to the level in a control sample is indicative of a need for treatment;
- and administering an effective amount of an agent to the subject thereby treating the depression or psychosis in the subject, wherein the agent is a SOD1 mimetic, a C3 convertase inhibitor, a LIF supplement, a LIF receptor agonist, or a ROS scavenger.
Dependencies are inferred from the claim text.